Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) hit a new 52-week low during mid-day trading on Saturday . The company traded as low as $7.18 and last traded at $7.79, with a volume of 4662321 shares traded. The stock had previously closed at $11.95.
Separately, HC Wainwright reaffirmed a "buy" rating and set a $38.00 target price on shares of Pliant Therapeutics in a research report on Friday, November 8th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $40.50.
Read Our Latest Research Report on Pliant Therapeutics
The stock has a market capitalization of $474.02 million, a P/E ratio of -2.33 and a beta of 1.03. The company has a fifty day moving average of $12.67 and a two-hundred day moving average of $12.94. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.26 and a quick ratio of 10.26.
Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($0.95) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.04. On average, equities analysts anticipate that Pliant Therapeutics, Inc. will post -3.65 EPS for the current year.
In other news, CEO Bernard Coulie sold 52,419 shares of the firm's stock in a transaction on Friday, January 17th. The stock was sold at an average price of $11.20, for a total transaction of $587,092.80. Following the completion of the sale, the chief executive officer now directly owns 430,517 shares of the company's stock, valued at $4,821,790.40. This trade represents a 10.85 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Hans Hull sold 15,936 shares of the firm's stock in a transaction on Friday, January 17th. The stock was sold at an average price of $11.20, for a total value of $178,483.20. Following the sale, the insider now directly owns 211,558 shares of the company's stock, valued at approximately $2,369,449.60. This represents a 7.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 91,855 shares of company stock valued at $1,026,628. 6.40% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. R Squared Ltd bought a new position in Pliant Therapeutics during the fourth quarter valued at about $33,000. Atria Investments Inc bought a new position in Pliant Therapeutics during the third quarter valued at about $112,000. China Universal Asset Management Co. Ltd. raised its holdings in Pliant Therapeutics by 65.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,694 shares of the company's stock valued at $131,000 after buying an additional 4,607 shares in the last quarter. Intech Investment Management LLC acquired a new stake in shares of Pliant Therapeutics in the third quarter valued at about $145,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Pliant Therapeutics in the third quarter valued at about $342,000. 97.30% of the stock is currently owned by hedge funds and other institutional investors.
Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Pliant Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pliant Therapeutics wasn't on the list.
While Pliant Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.